Document is current
Any future updates will be listed below
-
Authors
Dörrich, Marion
Balk, Matthias
Heusinger, Tatjana
Beyer, Sandra
Mirbagheri, Hamed
Fischer, David J.
Kanso, Hassan
Matek, Christian https://orcid.org/0000-0001-8528-8581
Hartmann, Arndt
Iro, Heinrich
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
Gostian, Antoniu-Oreste
Kist, Andreas M. https://orcid.org/0000-0003-3643-7776
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KD2211A, 01KD2211B, 01KD2211B)
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 21 July 2025
First Online: 4 August 2025
Competing interests
: A.H. declares general disclosures (Honoraria for lectures or consulting/advisory boards for AbbVie, AstraZeneca, Biocartis, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, QUIP GmbH, and other research support from AstraZeneca, Biocartis, Cepheid, Gilead, Illumina, Janssen, Novartis, Owkin, Qiagen, QUIP GmbH). ME declares general disclosures (Personal fees, travel costs, and speaker’s honoraria from Zytomed Systems, Merck, Eisai, MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS, BicycleTX, QuiP GmbH; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH, BicycleTX; advisory roles for Ferring, Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS, BicycleTX, Merck; member of the clinical advisory board of BicycleTX; stock ownership: BicycleTX.). All other authors declare no competing interests.
